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Abstract: The area of process change over time is a particular concern in healthcare, where patterns
of care emerge and evolve in response to individual patient needs. We propose a structured approach
to analyse process change over time that is suitable for the complex domain of healthcare. Our
approach applies a qualitative process comparison at three levels of abstraction: a holistic perspective
(process model), a middle-level perspective (trace), and a fine-grained detail (activity). Our aim was
to detect change points, localise and characterise the change, and unravel/understand the process
evolution. We illustrate the approach using a case study of cancer pathways in Leeds where we
found evidence of change points identified at multiple levels. In this paper, we extend our study by
analysing the miners used in process discovery and providing a deeper analysis of the activity of
investigation in trace and activity levels. In the experiment, we show that this qualitative approach
provides a useful understanding of process change over time. Examining change at three levels
provides confirmatory evidence of process change where perspectives agree, while contradictory
evidence can lead to focused discussions with domain experts. This approach should be of interest to
others dealing with processes that undergo complex change over time.
Keywords: process mining; cancer pathways; process change; concept drift; multi-level process
comparison
1. Introduction
Process mining research projects, like other data analytics projects, work with data collected over
months or years. Those projects are generally started by assuming that there no change occurred to
the processes during the period of study. In reality, there is a high possibility that changes occurred in
both the process and the data generated by that process. In healthcare, this is a particular concern
because patterns of care emerge and evolve in response to individual patient needs, care procedures,
and Electronic Healthcare Record (EHR) system changes, among other reasons. Those changes happen
through complex interactions between people, processes, technology and changing organisational
structures. It is important to identify and model process change over time in healthcare process
mining so that intended changes can be monitored and unintended changes can be investigated
and understood.
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The term ‘concept drift’ has been used by the machine-learning community to describe the changing
nature of processes over time [1]. Process mining community adopted this term to describe the dynamic
nature of the process or the data recorded about the process. There is a growing body of literature
exploring new approaches to analyse concept drift [2–4]. There are three challenges when dealing
with concept drift: (1) change point detection, (2) change localisation and characterisation, and (3)
change process evolution. Change point detection is about detecting a process change and localisation
is about determining the period within which this change occurred. Change characterisation aims to
understand the nature of a change and describe the elements of a process change. Change process
evolution aims to understand the evolution of a process over time.
Process change analysis is commonly done by constructing process models from different time
windows in a large dataset and comparing them to each other to identify process changes. This approach
is related to process comparison, which has been widely applied for conformance checking, where
a reference model is compared to the event log recording the real process execution [5]. A process
comparison approach to process change analysis proposed by Partington et al. [6] included defining
comparison points based on various metrics. However, Partington et al.’s approach was used to
compare processes between different hospitals and is not directly applicable to process change analysis.
Furthermore, Partington et al.’s approach required clinical understanding to select specific clinical
metrics that vary between different clinical domains. Bolt et al. [7] proposed another process comparison
approach based on the differences in activity frequencies and percentages in the logs. This approach
facilitated a detailed comparison between each activity in two logs, but not directly between processes.
Both works by Partington et al. and Bolt et al. are not directly related to process change analysis, but
the underlying ideas of comparison can be used for analysing process change over time. While each of
these approaches provide some insight into process change, there is no omnibus method that benefits
from the advantages and perspectives of them all.
In this paper, we present an exploratory study where we discover and analyse changes over time
in complex longitudinal healthcare data. Our aim was to adopt a multi-level approach to detect, localise
and characterise process change. Our case study was drawn from the EHR system of the Leeds Teaching
Hospital National Health Service Trust (LTHT). The LTHT hosts one of the UK’s largest cancer centres
(Leeds Cancer Centre). We examined process data on the routes to diagnosis of endometrial cancer
patients over 15 years (2003–2017). Our previous literature review found that process mining has been
used in oncology and shows promising results to support process analytics [8]. In earlier work with
the Leeds Cancer Centre data [9,10], we had assumed that there were no changes to the process during
the time period. We were aware that the period was long, that the organisation, system, and people
had evolved and changed over time, but we were not aware of specific process changes before we
commenced the study. However, our previous experience process mining MIMIC-III, an open-access
database [11,12], showed that a system change can affect the discovered process. We were fortunate to
have access to the Leeds EHR system developed in-house, Patient Pathway Manager (PPM) [13,14],
along with access to the parties involved in the treatment process: clinical staff, senior clinicians,
the training team, and the software developers of the PPM system. Our multi-level process change
analysis method [15] detected changes that can be explored and discussed with those parties to identify
potential causal links between changes detected in the data and in practice.
2. Materials and Methods
2.1. General Methodology of the Multi-Level Process Change Analysis
Our general method combined the well-established Process Mining Process Methodology
(PM2) [16] with concept drift analysis [4]. A process change analysis proposed by Bose et al. [4]
suggested three steps: process change detection, localisation and characterisation, and unravelling
process evolution. We proposed an approach to apply those steps through a process comparison
at three different levels: process model, trace, and activity levels. We used our approach to analyse
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a case study of the route to the diagnosis of endometrial cancer. Our general methodology is shown in
Figure 1.
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As presented in Figure 1, planning defined the business process of interest, the research questions,
and team members involved in this study. Our study focused on the route to diagnosis of endometrial
cancer. Our research question was “How does the process evolve over time?”. Our team consisted
of computer scientists and oncologist. Extraction included steps to select the 11 events recorded as
part of a patient’s process from referral by a General Practitioner (GP referral) until the endometrial
cancer diagnosis. In Data processing, we split the event log into sub-logs consisting of traces of
patients based on the diagnosis year. Some filtering and aggregation were conducted based on clinical
experts’ judgements. Process mining and analysis applied three steps of process change analysis at three
different levels of process comparison. Finally, the Evaluation stage involved discussion, verification
and assessment of the validity of the findings, with clinical experts.
The main components of our study can be expressed in the following definitions.
Definition 1 (Event logs and traces). An event log, E, is a set of events described by a case_id,
an activity name, and a timestamp, (c, a, t). An event describes an activity, a, which happened in
a particular case, c, at a timestamp, t. A trace, T, is a temporal sequence of events that occurred in a case,
where T ε E. In this study, a case represents a patient who has a set of events between the timestamps
of referral and diagnosis of endometrial cancer.
Table 1 shows a fictitious but illustrative event log similar to the event log used in this study.
This event log consists of the timestamped events of two patients. The first patient (P001) had
four recorded events that can be written as a trace (referral–investigation–multi-disciplinary team
(MDT) review–diagnosis). The second patient (P002) had five events that can be written as a trace
(referral–outpatient–MDT review–diagnosis–surgery).
Table 1. An illustrative event log.
Case_ID Activity Timestamp (YYYY-MM-DD)
P001 Referral 2020-01-06
P001 Investigation 2020-01-13
P001 MDT Review 2020-01-17
P001 Diagnosis 2 20-0 -31
P002 Referral 2020-01-21
P002 Outpatient 2020-01-22
P002 MDT Review 2020-01-31
P002 Diagnosis 2020-02-10
P002 Surgery 2 20-02-10
. . . . . . . . .
MDT = Multi-Disciplinary Team.
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Definition 2 (Sub-logs). A sub-log, S, is a partition of an event log, E, based on partitioning criteria.
The partitioning should be done in such a way that a trace is grouped into a sub-log with no duplication
between sub-logs. In this study, the event log was divided into sub-logs based on the year of diagnosis
of each patient. There are clearly many partitioning options that could be adopted.
Figure 2 shows the algorithm used in this study to create sub-logs. The year of diagnosis was used
because the diagnosis was the starting point in the selection criteria of patients included in this study.
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Definition 3 (Process models). A process model, M, is a directed graph representing the traces, T, in
the event log, E. A process model consists of nodes representing activities, a, and arcs representing
the possible paths, p, from one activity to another. A process model can be discovered using standard
process mining algorithms. A process model might have additional components, such as the percentage
of a and p to all activities and paths in E, respectively.
2.2. Process Change Analysis
The analysis of the sub-logs was based on selected metrics at the process model, trace, and activity
levels to describe the multi-level behaviour of the processes of interest. A summary of the metrics used
in this study is presented in Table 2.
Table 2. Metrics for multi-level process analysis.
Level Metrics Description
Model Replay fitness A measure of how many traces T from the sub-log S can be reproduced inthe process model M, with penalties for skips and insertions; range 0–1.
Precision
A measure of how ‘lean’ the model M is at representing traces T from
the sub-log S. Lower values indicate superfluous structure in the model M;
rang 0–1.
Generalisation
A measure of generalisability as indicated by th redundancy of nodes in
the model M. The more redundant the nodes, the more variety of possible
traces T that can be represented; range 0–1.
Trace Duration The number of days of trace T from Referral to Diagnosis.
Variant proportion The proportion of variants in the sub-log S that were one of the most frequentvariants in the complete log E.
Activity Frequency The number of cases c undergoing an activity a in the sub-log S.
Percentage The percentage of cases c undergoing an activity a out of all cases ina sub-log S.
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For the model-level comparison, we investigated the performance of four miners in ProM 6.8.
Those four miners are Integer Linear Programming (ILP), the interactive Data-Aware Heuristics
Miner (iDHM), the Inductive Miner (IM), and the Inductive Miner—Infrequent (IMf). These miners
represent discovery algorithms from three different approaches. ILP represents region-based miners
that construct a Petri net from a description of the behaviour in a transition system [17]. The iDHM
represents heuristics-based miners that use a process-representation language in causal nets [18].
The IM and IMf represent two variants of inductive-based miners that construct a process tree to
guarantee re-discoverability [19]. The IM discovers a complete graph, while IMf excludes infrequent
traces. For all four miners, we used the default parameters in ProM since parameter optimisation
is outside the scope of this paper. The general process model was built from the complete event
log from 2003 to 2017. The model-level behaviour was described by the replay fitness, precision
and generalisation [5] of each sub-log (i.e. each calendar year) to the general model.
The trace-level behaviour was described by the durations and variants of the traces in the sub-logs
using bupaR [20]. The duration of referral to diagnosis was analysed further in relation to the new
28-day waiting time target as set by the Cancer Task Force. Trace variants were explored in more detail
to analyse types of investigations undertaken during patient treatment.
The activity-level behaviour was described by activity frequency and its percentage in the sub-logs.
A visual–analytic approach was adopted to identify possible changes by comparing the visualisations
of these descriptions of process behaviour. The comparison was done quantitatively. As a follow-up
on the deeper analysis of the investigation events, we explored different types of investigations in
the activity-level comparison.
2.3. The Route to the Diagnosis of Endometrial Cancer: A Case Study
Our previous literature review found that process mining has been used in oncology and shows
promising results to support process analytics [8]. We reviewed the case studies examined in
publications and found that there were only 14 case studies between 2008 and 2016 and they were
dominated by a well-prepared dataset in the Business Process Intelligence Challenge (BPIC) 2011.
This suggested the lack of available datasets for process mining in oncology. General complaints about
providing real case studies arise because of limited access to hospitals, difficulties in granting access due
to confidentiality and ethical concerns, and the limited number of cases in oncology. Our case study was
based on a real dataset extracted from the PPM EHR system of the LTHT as a large cancer centre with
the additional advantage of direct access to expertise in the hospital. Another extract from the same
database has been used in a previous study [9] where we described the provenance and characterisation
of the database. We explored and made sure that this dataset contained the required components for
process mining and thus was suitable to be used in this study.
Our case study focused on the route to the diagnosis of endometrial cancer of Leeds patients
over an extended fifteen-year time period. Endometrial cancer is one of the most common cancers
in the gynaecology department, and it was understood that the procedure for endometrial cancer
treatment had not been changed radically within the last fifteen years. We used an event log from
the PPM EHR that has been anonymised and cleaned, as documented in full in [9]. We extracted
events from GP referral to the diagnosis of endometrial cancer. One of the important performance
indicators in cancer treatment is the route to diagnosis [21] or cancer waiting time [22]. In the UK,
the performance of cancer waiting time is monitored by Public Health England and forms a key
benchmark for high-quality cancer care. In 2015, the Cancer Taskforce recommended the introduction
of a new 28-day faster diagnosis standard. Changes to the cancer waiting time system and dataset
were introduced from April 2018 to mark the start of the implementation of this new standard, which
was fully implemented in 2020. Even though our data are on 2003–2017 cohorts, we could use our
cohorts to see if the historical data would fit into the new standard.
Endometrial cancer is a common cancer in women who have been through the menopause.
This cancer affects the female reproductive system with the most common symptom being unusual
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vaginal bleeding. This symptom is usually checked in a GP consultation and then the patient is referred
to an oncology specialist (gynaecologist). The specialist conducts some tests (investigations), such as
an ultrasound scan, a hysteroscopy or a biopsy. The results of the investigations are then discussed in
a multi-disciplinary team (MDT) review to gain a consensus from clinical experts. If diagnosed with
endometrial cancer, the cancer stage will be defined by further investigations [23].
All of these events have been coded and recorded in the PPM EHR at the Leeds Cancer Centre
since 2003. The extracted event log should therefore consist of those records and is a rich data source
for process mining of the pathways of interest. The PPM EHR consists of at least 50 tables, including
nine tables relevant to our study of the pathways from GP referral to an endometrial cancer diagnosis.
Those nine tables contain broad categories of activity, such as referrals, outpatients, and diagnosis.
3. Results
3.1. Data Extraction and Data Processing Stages
We created the study cohort by applying four selection criteria. Patients were included in the study
if they had:
i. a legitimate care relationship with the LTHT,
ii. a primary diagnosis of endometrial cancer (ICD-10 code C54 or C55),
iii. an endometrial cancer diagnosis between 2003 and 2017,
iv. been diagnosed at a maximum of 120 days after referral to an oncology specialty.
The last criterion was decided based on discussions with clinical experts who argued that a referral
period greater than 120 days is implausibly long for the events to be related. By applying those four
selection criteria, we selected 943 out of 1126 endometrial cancer patients (84%). There were 65,200
events selected based on all patients or 58 events per patient on average.
We extracted all time-stamped events between GP referral and diagnosis from the selected patients.
This step resulted in 339 different activity types. For our study, we focused simply on the broad
categories of activity represented by the nine tables. We separated admissions and discharges from
their combined table and separated diagnostic surgery events from the surgery table. The resulting 11
activities agreed with the prior knowledge of our clinical co-authors. Those activities are presented
in Table 3 along with the number of occurrences, the number of patients and the percentages.
The percentage of the occurrence was calculated against the total number of records. The percentage
of patients was calculated by the total number of patients rather than records and so did not add up
to 100%. The event log contained 7967 events with a minimum of 2, a median of 6, a mean of 6.3,
and a maximum number of 12 events per patient.
Table 3. The activity list.
# Activity Name Occurrence (%) Patients (%)
1 Referral 943 (12) 943 (100)
2 Diagnosis 943 (12) 943 (100)
3 Investigation 1455 (18) 891 (94)
4 DiagnosticSurgery 1025 (13) 797 (85)
5 Pathology 1196 (15) 540 (57)
6 Admission 661 (8) 285 (30)
7 Discharge 581 (7) 193 (20)
8 Consultation 346 (4) 128 (14)
9 MDT Review 338 (4) 199 (21)
10 Surgery 248 (3) 234 (25)
11 Outpatient 231 (3) 135 (14)
Total 7967 (100)
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3.2. Process Model Comparison
Table 4 shows the replay fitness, precision and generalisation of the four miners evaluated. We
used the four miners with the default parameters in ProM and represented the maximum number of
traces and activities. The ILP showed perfect precision and high generalisation, but had the lowest
replay fitness. This means that the ILP discovered a model that is highly generalisable and precise, but
does not fit a high percentage of the individual traces. The IM showed an optimal replay fitness, but
low precision and zero generalisation. The IM focused on discovering a model that is fitted for all traces
in the event log, but is not precise nor generalisable. The IMf is better than IM for precision, worse
for replay fitness, but similarly poor for generalisability. Both IM and IMf have 0.00 generalisation,
which suggests that both models are not generalisable for future behaviours. The iDHM process model
showed a model with high replay fitness, precision, and generalisation. While ILP and iDHM both
performed well, we favoured iDHM because ILP’s precision of 1.00 suggests an overly specified model
while performing relatively poorly for replay fitness.
Table 4. Summary of process model quality.
Miner Replay Fitness Precision Generalisation
ILP 0.72 1.00 0.99
IM 1.00 0.46 0.00
IMf 0.92 0.92 0.00
iDHM 0.81 0.83 0.99
ILP = Integer Linear Programming; IM = Inductive Miner; IMf = Inductive Miner-Infrequent; iDHM = Interactive
Data-Aware Heuristics Miner.
The general process model showed in Figure 3 is based on iDHM of the complete log for
the full 15 years. For simplicity, we present the process model of the eight most-frequent activities
and the most-frequent paths between them. The infrequent activities that were omitted from the process
model are outpatient, consultation, and MDT review. The outpatient activity appeared in 149 out of
943 patients (16%), consultation appeared in 152 out of 943 patients (16%), and MDT review appeared
in 231 out of 943 patients (24%).
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representative of each yearly sub-log (median [inter-quartile range]: replay fitness = 0.86 [0.10], 
precision = 0.78 [0.03], and generalisation = 0.93 [0.06]). Figure 4 shows that all measures were similar 
throughout the years. Our qualitative assessment suggested three candidate changes: 2004, based on 
the increased replay fitness and generalisation; 2011, based on a drop in replay fitness and increase 
Figure 3. The Data-Aware Heuristics Miner (iDHM) process model. Originally produced by the iDHM
plugin in ProM 6.8, showing the process model of the pathway from referral to diagnosis. The pathway
flows from left to right, with rectangles representing activities and arrows as flows from one activity to
the other. The numbers on the arrows show the number of patients with activity flows to other activities.
The event log was divided into 15 sub-logs based on the year of diagnosis. We then tested
each sub-log for conformance against the general process model. The model remained reasonably
representative of each yearly sub-log (median [inter-quartile range]: replay fitness = 0.86 [0.10],
precision = 0.78 [0.03], and generalisation = 0.93 [0.06]). Figure 4 shows that all measures were similar
throughout the years. Our qualitative assessment suggested three candidate changes: 2004, based on
the increased replay fitness and generalisation; 2011, based on a drop in replay fitness and increase in
generalisation; 2016, based on the increased replay fitness and precision. The three identified periods
of potentially significant change are 2003–2004, 2010–2011 and 2015–2016.
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3.3. Trace Comparison
Figure 5 shows a box plot representing the profile of trace duration from referral to diagnosis for
each yearly sub-log. The box plot shows no obvious qualitative pattern based on the distribution of
the duration, except on the inter-quartile range (IQR). The IQR is generally decreasing throughout
the years, with some exceptions. Based on these results, we identified five candidate periods of change:
2005, where the IQR increased from 42 to 71 days (68%); 2008, where the IQR increased from 32 to 45
(39%); 2010, where the IQR increased from 34 to 49 days (44%); 2011, where the IQR increased from 49
to 50 days (2%); 2015, where the IQR increased from 41 to 48 days (18%).
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Figure 5. Boxplot of nu ber of days fro GP referral to diagnosis by year of diagnosis. Dashed line
shows target duration (28 days). The shaded boxes show the periods where change might have occurred.
Additionally, in Figure 5, we included a dashed line showing a target duration of 28 days.
This duration is the new waiting time target set by the Cancer Task Force in 2015. This new target
was introduced from April 2018 and was fully implemented in 2020. Even though our data are on
the 2003–2017 cohort, we show this target to analyse whether the historical data would fit into the new
standard. It is shown in Figure 5 that the median durations in 2009 and 2013 were fit to the targeted
duration, and 2017 was the first time that the year’s interquartile range was below the targeted duration.
The top ten trace variants (representing 52%) of the general model and the presence of those variants
over the years are shown in Figure 6. Those top ten trace variants show only seven activities, excluding
surgery. The first variant is the sequence of referral (R), investigation (I), pathology (P), diagnostic
surgery (DS) and, finally, a diagnosis (D) of endometrial cancer. This variant is the most-common
pathway of the patients in the cohort. The second variant is similar to the first one, but with no record
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of investigation. We discussed this with the clinical experts and found that this reflected a process
change in the EHR system, where investigation had not been recorded in the system in the early years.
The third variant is similar to the first, except that the patients were admitted after an investigation.
The three most common variants (median [IQR]) are R–I–P–DS–D (19 [9]%), R–P–DS–D (10 [7]%),
and R–I–A–P–DS–D–Di (6 [3]%). The qualitative distinction between the years is the wavering trend of
the first variant and the decreasing trend of the other variants. For example, variant 2 (R–P–DS–D),
variant 5 (R–D) and variant 9 (R–DS–D) were frequent in 2003, but became infrequent in later years.
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3.4. Activity Comparison
Figure 7 shows a plot of the total number of patients undergoing each of the main activities over
the years. In 2003–2004, there was a sudden increase in almost all activities. In 2010–2011, there was
a sudden increase in almost all activities except on discharge. Meanwhile, in 2015–2016, there was
a sudden decrease in all activities. These three periods of change were also suggested in Section 3.2
when reviewing the model level.
Int. J. Environ. Res. Public Health 2020, 17, x FOR PEER REVIEW 9 of 17 
excluding surgery. The first variant is the sequence of referral (R), investigation (I), pathology (P), 
diagnostic surgery (DS) and, finally, a diagnosis (D) of endometrial cancer. This variant is the most-
common pathway of the patients in the cohort. The second variant is similar to the first one, but with 
no record of investigation. We discussed this with the clinical experts and found that this reflected a 
process change in the EHR system, where investigation had not been recorded in the system in the 
early years. The third variant is s milar to the first, except that the patients were admitted after an 
investigation. The thre  ost common variants (median [IQR]) are R–I–P–DS–D (19[9]%), R–P–DS–
D (10[7]%), and R–I–A–P–DS–D–Di (6[3]%). The qualitative distinction between the years is the 
wavering trend of the first variant and the decreasing trend of the other variants. For example, variant 
2 (R–P–DS D), variant 5 (R–D) and vari n  9 (R–DS–D) were frequent in 2003, but became infrequent 
in later ye s. 
 
Figure 6. Summary of the trace variant comparison (2003–2017). Size represents the percentage of 
trace variants over the number of patients diagnosed in each year. 
. . i i  i  
i     l    l   i  i     i  i i i   
 .  ,     i  i  l  ll i i i .  ,   
   i  l st al  activities except on discharge. Meanwhile, in 2015–2016, ther  was a 
sud en decrease in all activit es. These thre  periods of change were also s este  i   .  
    l. 
 
Figure 7. The total number of patients undergoing each of the main activities (2003–2017). The shaded 
areas show the periods where change might have occurred at the activity level. 
We plotted the percentage of each activity for the number of patients each year, as presented in 
Figure 8. The activities were grouped into frequent activities, occurring in at least 60% of patients, 
infrequent activities, occurring in less than 60% of patients, and highly varied activities in between. 
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We plotted the percentage of each activity for the number of patients each year, as presented in
Figure 8. The ac iviti s were gr uped into frequent activities, ccurri g in at least 60% of pa ients,
infrequent activities, occur in in less than 60% of p tients, and highly varied activities in between.
The thr e most frequent activities in all years (median [i ter-quartile range]) are pathology (93 [7]%),
diagnostic surgery (87.5 [9]%), and investigation (80 [16]%). The four most infrequent activities are MDT
review (12 [20]%), outpatient (13 [7]%), surgery (15.5 [23]%), and consultation (16 [24]%). Qualitatively,
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the period of 2010-2011 was marked by a change in the frequency of the four infrequent activities,
while Discharge was decreased to be lower than the four infrequent activities. In 2013, the frequency of
the infrequent activities was increased, except for outpatient.
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Figure 8. Percentage of activity presence by the number of patients each year. The solid black
lines represent frequent activities; the solid grey lines represent infrequent activities and highly
varied activities. The shaded areas show the potential change periods at the activity level. Referral
and diagnosis occurred in 100% of patients and are not presented for simplicity purposes.
Our discussion with clinical experts suggested that investigation is the most-important activity in
the pathway of referral to the diagnosis of cancer. We then analysed the investigation by examining
the occurrence and the number of patients undergoing different categories of investigation. Our clinical
experts (K.Z. and G.H.) categorised the investigation labels into 17 categories.
Table 5 shows a summary of the categorisation, the occurrence and the number of patients
undergoing the investigation categories. It is shown that the most frequent category is unknown
(498/34%), which shows the nature of incomplete records in the EHR system. It is followed by diagnostic
sampling, ultrasound scans (USS), MDT, plain film, MRI, and CT. The ten other categories occurred
less than five times in the event log, leaving only six frequent categories to analyse. Those six frequent
categories are diagnostic sampling, USS, MDT, plain film, MRI, and CT.
Table 5. Summary of investigation categories. Occ (%) shows the number of occurrences and the percentage
of the total occurrences in the event log. N (%) shows the number and percentage of patients undergoing
a specific investigation category.
# Category Investigation Label Occ (%) N (%)
1 Unknown Unknown 498 (34) 441 (57)
2 Diagnostic Sampling
Aspiration of lesion of breast, biopsy of lesion
of organ ‘Not Otherwise Classified’, gynae
cytology, non-gynae cytology, Pleural
aspiration ± biopsy
233 (16) 218 (28)
3 USS
Doppler ultrasound, endoscopic ultrasound,
transabdominal ultrasound, transvaginal
ultrasound, ultrasound
214 (15) 210 (27)
4 MDT Films reviewed at MDT meeting 184 (13) 146 (19)
5 Plain Film Chest X-ray, sinus X-ray, skeletal survey 136 (9) 117 (15)
6 MRI MRI -con, MRI (con unknown), MRI +con 107 (7) 106 (14)
7 CT CT -con, CT (con unknown), CT +con, CTcolo oscopy virtual 58 (4) 55 (7)
8 Investigative Surgery Investigative surgery 4 (0.3) 4 (0.5)
9 Screening Mammogram 4 (0.3) 4 (0.5)
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Table 5. Cont.
# Category Investigation Label Occ (%) N (%)
10 Vascular Imaging
Angiography, angioplasty, Magnetic Resonance
Angiography, Magnetic Resonance Venogram,
venogram
4 (0.3) 4 (0.5)
11 Clinical Examination Clinical examination 3 (0.2) 3 (0.4)
12 Bone density Bone densiometry DXA 2 (0.1) 2 (0.3)
13 Nuclear Medicine NMI, PET 2 (0.1) 2 (0.3)
14 Other Other 2 (0.1) 2 (0.3)
15 Urine Sample Urine 2 (0.1) 2 (0.3)
16 GI Imaging
Ba enema, barium enema, barium swallow,
gastrografin enema, gastrografin swallow,
MRCP, proctogram
1 (0.1) 1 (0.1)
17 Nuclear MedicineImaging Bone scan 1 (0.1) 1 (0.1)
-con = without contrast dye, +con = with contrast dye.
Figure 9 shows a plot of the number of occurrences of the five most-frequent investigation
categories over the years. We found five periods where changes might have happened, based on
the occurrence of investigation categories. In 2004, all investigation categories except diagnostic
sampling had increased with a mean increase of 13.6. In 2005, all investigation categories were
increased with a mean of 15, except MRI, which was slightly decreased from the previous year. In 2010
and 2011, all investigation categories were increased with averages of 14.6 and 27, respectively. In 2014,
all investigation categories were decreased, with an average of 19. These candidate changes in 2004,
2010 and 2011 agreed with the candidate changes identified by the activity presence (Figure 8).
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3.5. Additional Analysis
We conducted the same analysis of the trace-level comparison to examine the 17 investigation
categories. This additional analysis can be seen as a way to analyse the process at a different level of
granularity. A summary of the top 10 trace variants with the occurrence and percentage is shown in
Table 6.
Table 6 shows that the top ten trace variants from the general model represented 44.7% of all
traces and included only five types of Investigation, which were USS, MRI, MDT, diagnostic sampling,
and plain film. The low number of traces represented in the top ten trace variants imply the high
variability of the sequence of investigation categories undertaken by the patients. Of all 768 cases
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with recorded investigations, there are 182 trace variants (24%). The most-common trace variant is
MRI–MDT (7.3%), followed by the second trace variant MDT–diagnostic sampling (6.8%) and the third
trace variant is MDT–plain film–diagnostic sampling (5.9%).
Table 6. Summary of the top ten trace variants based on the investigation categories.
# Trace Variants Occurrence (%)
1 MRI–MDT 56 (7)
2 MDT–Diagnostic Sampling 52 (7)
3 MDT–Plain Film–Diagnostic Sampling 45 (6)
4 MRI–MDT–Diagnostic Sampling 39 (5)
5 MDT 36 (5)
6 Diagnostic Sampling 30 (4)
7 MRI–MDT–Plain Film–Diagnostic Sampling 24 (3)
8 Plain Film–Diagnostic Sampling 21 (3)
9 MRI 20 (3)
10 USS–MRI–MDT–Diagnostic Sampling 20 (3)
Total 343 (44.7)
4. Discussion
We analysed our case study of endometrial cancer care in Leeds Cancer Centre following the PM2
methodology. We focused on the first five stages of PM2 (excluding process improvement and support)
to exemplify the appropriate application of our novel, multi-level, exploratory approach. Our approach
supports the exploration for unknown process changes through a qualitative, multi-level perspective
for detecting, localising and characterising the changes in processes. Graphical data visualisations
make use of humans’ natural pattern-seeking capacities and support discussions with domain experts
about process evolution and change. We found that such discussions helped us to reflect on the nature
of the process change over time and to generate hypotheses about potential causal links between
changes detected in the data and changes in practice.
These hypotheses can then be tested by further, more tightly focused process and data analysis.
In that respect, our approach is perhaps just a starting point for further exploratory studies. In this
case study, we split a fifteen-year event log into 15 yearly sub-logs. Further analysis can be done to
examine the division of the log into months, weeks, days or hours to isolate potential change events of
interest. It is important to note that the shorter the duration of each division will lead to a smaller
number of traces in each division, which could potentially lower the confidence in the results.
We based our approach on Bose et al.’s process change analysis: detection, localisation
and characterisation, and unravelling [4], and Partington et al.’s process comparison [6]. Bose et al.
suggest that the best place to start analysing process change is by detecting that a process change has
taken place. If that is the case, then the next steps are to identify the time periods at which changes
happened and characterise the nature of the change. As an improvement to Bose et al.’s approach, we
detected the changes from multiple levels, rather than just at the activity level. The process comparison
approach described by Partington et al. requires the domain expert to pre-characterise the expected
differences that they want to detect and localise. In contrast, our approach did not require prior
specification of the changes. Instead, we used domain experts in the later stage of what Bose et al.
describe as “Unravelling”. This approach supports initial exploration without over-burdening domain
experts or when they are not able to pre-specify the expected differences.
4.1. Change Detection
Changes were detected at all three levels: five at the trace level and three at model and activity
levels. From our blinded exploration of our case study process, we cannot attest to the validity of these
detections nor can we know about any true process changes that were not detected. Our approach
visualised the trend over time in three different levels of comparison and presented those visualisations to
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the experts. We approached the change detection through discussions with clinical experts and members
of the developer teams to identify several possible changes in the clinical and technical aspects that
might affect the changes evidenced in the data. Future work using simulations could attempt to
determine the sensitivity of our suggested approach to changes in the magnitude and characteristics of
process changes.
4.2. Change Localisation and Characterisation
With assumptions that the detected changes were true changes, we localised the changes to
the 2010–2011 and 2015–2016 periods. These localisations were supported by an agreement between
changes in metric values across multiple levels. Our multi-level approach shows its usefulness in
the sense that the changes detected at one level can guide a focused investigation of the same period
at other levels. For our case study, despite detection at the model and activity level, no change was
independently detected at the trace level in the 2003–2004 period. There are also possible changes in
2005 and 2008 based on the duration analysis, where the IQRs of durations were increased. A review of
the trace durations led us to consider that the median duration in 2016 was the first example of a year’s
median duration lying outside the interquartile range of the previous year. Nevertheless, agreement in
the localisation of changes supports the confidence of the change detection.
The aforementioned post-hoc review of trace durations is an example of how our approach
facilitates change characterisation at levels where changes would not be found if levels were investigated
in isolation. The change characterisations of a level can provide evidence to support or refute
the characterisations of the other levels. The different median duration of traces was the only trace-level
characterisation of change in 2016. The strongest evidence for a 2016 change came from the sharp
decline in trace frequencies at the activity level and was supported by an unexpected rise in replay
fitness at the model level. This multi-dimensional perspective of a suspected change event informs
a more-rounded, complex picture of changes that can be taken to domain experts for discussion.
4.3. Unravelling Process Evolution
The rich characterisation stage provides the substance for a discussion with clinical experts as
we explain the mechanism and consequences of the change detection. Our discussion with clinical
experts to unravel process evolution found several findings based on three different levels of process
comparison. The process model discovered (Figure 3) has been agreed to reflect the simplified general
pathways from referral to the diagnosis of endometrial cancer. The perspective of the trace-level
comparison (Figure 5; Figure 6) confirmed that there was no significant change in the duration
and sequence from referral to diagnosis that the clinical experts were aware of. Clinical experts raised
concerns about some trace variants (Figure 6) that have an admission (A) without a discharge (Di)
(variants 7 and 10). Further analysis revealed that the discharge was not captured in the trace variants
because the discharge event happened after diagnosis. In the activity level comparison, clinical experts
highlighted their concerns regarding the finding that MDT review is one of the infrequent activities,
while, in fact, all patients would need to be discussed in an MDT review at some point during their
cancer treatment. Further discussions revealed that MDT reviews usually happen after a cancer
diagnosis. We learnt from these concerns that the definitions of the start and endpoints of the pathways
are crucial in defining what will be represented in the process model.
Another important discussion about the activity-level comparison is that the findings reflected
the evolving nature of the EHR system. For example, it is shown in Figure 6 that the outpatient
activity started to appear for patients diagnosed in 2006 and the consultation activity started to appear
for patients diagnosed in 2008. At the more fine-grained level of investigation, the MDT and USS
categories started to appear for patients diagnosed in 2004, while diagnostic sampling started in
2005. These evolutions were confirmed in a further discussion with the PPM development team,
where we learnt that the system was modified in these years to start recording these respected activities.
There were also improvements to the PPM system that introduced automatic imports from other
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systems (pathology, for example) that were previously captured manually. When the system was
improved, the data volume and the reliability of the data increased. There are opportunities for further
analysis to examine the effect of these changes in the system on the process over time.
4.4. Additional Analysis
Our additional analysis focused on the different types of investigation undertaken during patient
treatment. This was motivated by the initial finding that investigation was one of the most frequent
activities in the event log. Our clinical experts confirmed that a patient might have more than one
type of investigation and the choice of the most appropriate type of investigation required a complex
examination of patient conditions. We started our analysis by categorising the 53 different types
of investigation into 17 categories. We checked the occurrence of those 17 categories in the event
log and found that there were five frequent recurring categories within them. Those investigation
categories were then used in the deeper comparison of both the activity and trace levels over the years.
This additional analysis plays a role as an example of how our multi-level approach can be further
expanded to a deeper analysis of a specific part of the process of interest. In our case study, we expanded
our analysis to a deeper analysis of the investigation categories provided by the clinical experts.
4.5. Reflection on Our Proposed Approach
We conducted an analysis to compare the process models created using the four most-commonly
used miners in ProM 6.8. We expected to see that the general model was similar between miners, but we
saw otherwise. The resulting models are varied based on the different approaches followed by different
miners. We decided to discover our general process model using the iDHM plug-in [18], but another
option, being entirely informed by clinical guidance, might have produced different process models. We
used iDHM because its heuristic approach allowed us to obtain a process model at the desired level of
detail. The visualisations provided in the plug-in made it possible to explore the directly-follows graph,
dependency graph, causal net, or Petri net. We started our process model discovery by comparing
models discovered using four different miners, which are ILP, IM, IMf, and iDHM. We found that
iDHM performed well with a balanced quality of replay fitness, precision, and generalisation.
Another advantage evident in our approach is the splitting of the event log into sub-logs. We created
sub-logs based on the calendar year of diagnosis. It is equally reasonable to split the log to enforce
a uniform number of traces in each sub-log. The consequence of the first method is that the number
of traces in each sub-log varies and the consequence of the second is that the duration of the sub-log
varies. We addressed the consequence of our choice by analysing the frequency as a percentage instead
of the number of occurrences. This splitting approach is needed in blind cases where there is no prior
knowledge about any changes in the process. Otherwise, if there is a known process change, the event
log should be split into before and after change sub-logs.
5. Conclusions
This paper presented a multi-level approach to analyse process changes over time and showed its
applicability through a real-life case study. To the best of our knowledge, this is the first attempt to
leverage the advantages and perspectives of existing process change methods that have historically
focused on individual levels only. Our case study examined the pathways from GP referral to a diagnosis
of endometrial cancer in Leeds Cancer Centre patients. The event log generated in this case study
consists of events over a fifteen-year duration. It is representative of common EHR data with a long
study duration. The general method followed in this study is PM2, with a focus on the process analytics
stage to analyse process changes over time. Process change detection, localisation, and characterisation
were carried out at three different levels of comparison: model, trace and activity. This approach allows
for the detection of changes when comparing one year with another and answered the research question
of this study: How does the process evolve over time? The change period detected and characterised
in this study provided the substance for discussions with clinical experts and software development
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experts to unravel the process evolution. One important limitation of the proposed approach is that it
is not able to detect the exact point in time when the change actually occurred. Moreover, this approach
cannot detect changes back and forth during the same year. However, repeating the method with
a finer-grained time interval would allow the change point to be more accurately detected, with the risk
of having a smaller number of traces in each interval. Our additional analysis showed that we could
work out the granularity level of the analysis to examine the pathway at a deeper level and focus on
details of interest. For example, we examined investigations by inspecting them at a lower level of
granularity to analyse pathways of interest in more depth.
Future work could review the splitting method, the comparison metrics, the reference model
discovery, and the case complexity. The splitting method in this study was based on the calendar
year of diagnosis, but other methods might be suitable in other cases, such as splitting traces into
a uniform number in each sub-log or splitting based on a known change in interest. The comparison
metrics used in this study are defined to represent three different levels of detail, but further work
might examine other metrics for comparisons. The reference model discovery could be improved by
considering clinical guidelines in the reference model, or by including only valid traces in the discovery
step. This approach will also need to be tested on cases with different levels of complexity.
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